RxDoctor Payments Data

Steven Elieff, MD

Ophthalmology · Lewisville, TXNPI 1972511988

Payments from drug & device makers

$4,128in general payments, 2019–2025

Across 87 payments — averaging $47.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$401
  • AbbVie$386
  • Rxsight Inc$195
  • Bausch & Lomb Americas Inc.$157
  • Alcon$143
  • plus $424 from 12 others

What the payments were for

  • Consulting fees$2,13252%
  • Food & beverage$1,95847%
  • Gifts$391%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,128 in reported general payments places this provider in the 65th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$517,753
Medicare patients
1,871
Services billed
4,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost135$86,800
RestasisCyclosporine59$77,136
MieboPerfluorohexyloctane/Pf31$29,820
VyzultaLatanoprostene Bunod58$29,605
Cyclosporine42$24,237
ProlensaBromfenac Sodium62$20,874
Prednisolone Acetate563$17,227
BesivanceBesifloxacin Hcl68$14,626
Latanoprost1,387$14,031
Ketorolac Tromethamine277$12,774
SimbrinzaBrinzolamide/Brimonidine Tart39$11,568
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$10,393
CombiganBrimonidine Tartrate/Timolol25$9,140
Lotemax SmLoteprednol Etabonate38$9,094
Bimatoprost81$8,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$386$173,076219 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$157$59,42589 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Lotemax Sm$401$44,594168 claims
AlconSimbrinza$143$11,56839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Lewisville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →